Contraception

Studies presented at meeting showing efficacy of vaginal ring for contraception

Published in Blood Weekly, June 16th, 2005

Organon Pharmaceuticals USA announced that a new analysis reconfirms the contraceptive efficacy of NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) in all women, including women with higher body weight.

Additional data presented at the meeting demonstrate that NuvaRing provides better cycle control than an oral contraceptive and that it is well tolerated in extended regimens of use, beyond the standard 3-week cycle. The data were presented for the first time at the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in San Francisco, California.

The body weight data were derived from a secondary analysis of the efficacy...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-06-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry